Nanotheranostics and Precision Oncology

Nanotheranostics and Precision Oncology delves into the merging fields of cancer research and nanotechnology, offering a thorough review of the latest advancements in precision oncology. It begins with an exploration of cancer biology, illuminating the genetic foundations of oncogenesis alongside the cellular and molecular mechanisms driving cancer progression, metastasis, and drug resistance. This resistance remains the foremost challenge in cancer care. Across 28 chapters, the book addresses precision medicine's role in overcoming drug resistance, the importance of biomarkers, the interpretation of genetic analyses, and the shift toward personalized oncology. In addition, the book examines nanotheranostics' applications and mechanisms in cancer diagnosis and treatment, integrating them with precision oncology. It outlines the design, mechanism, and impact of nanoprecision medicine in cancer management. The final section considers the future of nanotheranostics in precision oncology and the challenges of translating these innovations from research to clinical practice. This comprehensive guide serves students, clinicians, researchers, and the pharmaceutical industry involved in nanomedicine, oncology, molecular biology, and precision medicine.

Table of Contents:
Section I: Cancer biology 1. Oncogenesis: Genetic basis Anum Chaudhry, Hania Shah and Shan e Zahra Sheikh 2. Hallmarks of cancer Fizzah Abid and Mudassir Khan 3. Cancer stem cells and tumor microenvironment Asma Areesh and Rimsha Sahr 4. Mechanisms underpinning invasion and metastasis Suhail Razak, Sameen Zafar and Tayyaba Afsar 5. Drug resistance in cancer Zarish Fatima, Tayaba Irfan, Maria Shabbir and Yasmin Badshah Section II: Precision oncology 6. Introduction to precision medicine Maryam Akmal and Iqra Mutiullah 7. Translational bioinformatics and precision medicine Maaz Waseem 8. Proteomics, metabolomics, and precision medicine Fizzah Abid and Ghulam Murtaza Kamal 9. Biomarkers and circulating DNAs as predictive molecular signatures Momina Tariq and Amaara Niazi 10. Genomic strategies for precision medicine Asma Latif, Farheen Zahid and Yasmin Badshah 11. Immunotherapy as a tool of precision medicine Haipeng Tao, Rameesha Fareed, Robert Dalton, Richa Gupta, Anjali Chauhan, Ravi Kumar, Srabasti Sengupta, Chong Zhao, Meiqi Shi and Muhammad Abbas 12. Clinically approved and under trial drugs for precision oncology Syeda Tahira Qousain Naqvi and Sana Khalid Section III: Nanotheranostics 13. Introduction to nanotheranostics Maisra Azhar Butt and Sobia Tabassum 14. Active and passive targeting of nanoparticles Maisra Azhar Butt and Sobia Tabassum 15. Nanocontrasts, nanoprobes, and nanosensors in cancer diagnosis Mushkbar Fatima, Laleen Saeed and Ramish Riaz 16. Nanoparticles as delivery vehicle for drugs and genes Aleena Haqqi and Zeemal Seemab Amin 17. Nanoparticles for thermal ablation Usama Masood, Tayyaba Hussain and Madeeha Chaudhry Section IV: Designing nanotheranostics for precision medicine 18. Current status of nanotheranostics in precision medicine Muhammad Abu Bakar Saddique, Muhammad Dawood Amjad, Huzaifa Tahir and Khired Sajid 19. Nano-immunotherapy Aneela Mustafa and Amna Hafeez 20. Stimuli-responsive nanotheranostics for precision medicine Sehrish Abbas and Bushra Uzair 21. Pharmacogenomics-based nanoprecision medicine Sidrah Hafeez and Shafia Maryam 22. ADME of nanoprecision medicines: Understanding the pharmacokinetics and pharmacodynamics of nanoprecision medicines Kaynat Iftekhar, Khired Sajid, Maria Rafiq and Mudassir Khan Section V: Challenges and future potentials 23. Challenges in translation of nanoprecision medicine Rimsha Ashraf, Tauqeer Hussain, Muhammad Summer and Shaukat Ali 24. Ethical and legal considerations in the use of nanotheranostics and precision medicine Amna Naheed Khan and Erum Dilshad 25. Economic challenges in use of nanotheranostics and precision medicine Areeba Ikram, Asma Rehman and Ramish Riaz 26. Biomarkers emerging in nanotheranostics and precision medicine Tooba Khan, Zainab Nisar Qureshi, Amaara Niazi, Mahnoor Ejaz and Khushbukhat Khan 27. Panomics, artificial intelligence, and precision medicine Mahnoor Basit, Momna Jamil, Rohma Jamil, Muhammad Haroon and Khushbukhat Khan 28. Nanotheranostics and precision medicine redefining the future of healthcare Roomisa Anis, Muhammad Huzaifah Qureshi, Fatima Irfan and Seyyedha Abbas

About the Author :
Dr. Ramish Riaz is an Assistant Professor and Head of Department, Medical Imaging Technology at Riphah International University. She completed her Ph.D. from NUST with a specialization in microbubble contrast agents. She has an M.Phil degree in Biotechnology with a specialization in cancer genetics. She is a graduate of Rawalpindi Medical University Imaging Technology Ramish worked on phase convertible nanodroplets as contrast agents and drug delivery agents during her PhD. Her major research interests include nanomedicine, drug delivery, and radiological contrast agents. She has multiple publications in the field of nanomedicine and wrote two Book Chapters on Cancer Genetics, & the Role of Nanomedicine in Cancer Therapy for Springer Nature. Dr. Maria Shabbir is an Associate Professor at NUST with around 8 years of academic experience. She has PhD degree in cancer genetics from Quaid e Azam University and a Post-doc form the University of Wisconsin, USA. She has received multiple grants and have many publications in credit in the field of cancer genetics. Her research group aims to identify cancer genes, which are genes that when mutated contribute to cancer development by promoting tumor cell growth and by conferring upon a cancer cell the ability to evade the cell cycle and cell death checkpoints that would normally control their growth. I am also interested in the networks and pathways that contribute to tumor development and how cancer genes work together to promote tumor evolution. Dr. Yasmin Badshah is an Assistant Professor at NUST. She completed her PhD from University of Punjab in Viral cancers. Her major research is in molecular alteration in viral cancers. Dr, Abdullah worked primarily on the validation of secretory serum-based biomarkers for easy detection of HCC during his Master's. Moreover, he also worked on the production of liposomes and magnesium oxide nanoparticles from microalgae. After his master's, he won the prestigious Chinese Government Scholarship and is currently enrolled in a PhD in Biochemistry and Biotechnology at the University of Chinese Academy of Sciences. He is currently working on heterologous expression, folding, and secretion of commercially important proteins from the yeast expression systems. He has 3 publications in ISI-indexed International journals and also wrote an invited Book Chapter on Cancer Genetics. Dr. Khushbukhat Khan, a Cancer Geneticist and co-founder of BioinfoXpert, boasts a distinguished career marked by several years of extensive engagement in oncology research and development, positioning her as a foremost authority in the field. Leveraging her exceptional expertise, she has been pivotal in driving the progress of biotechnology companies across the UK and USA, rendering two years of remote consultancy services that exemplify her impactful contributions.Simultaneously, Dr. Khan holds the esteemed position of Project Lead for oncology pre-clinical and clinical trials at Trials360, a distinguished subsidiary of Hayat Pharmaceutical Consulting located in California, USA. Her academic foundation includes a Ph.D. earned from the esteemed National University of Sciences and Technology (NUST), one of Asia's premier institutions.